Want to see AU:BDX full AI Analyst Report?
BDX Stock Chart & Stats
AU$0.10
>-AU$0.01(-2.06%)
At close: 4:00 PM EST
AU$0.10
>-AU$0.01(-2.06%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.16
Previous CloseN/A
Volume98.04K
Average Volume (3M)152.47K
Market Cap
AU$33.55M
Enterprise ValueAU$32.98M
Total Cash (Recent Filing)AU$1.59M
Total Debt (Recent Filing)AU$6.92M
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Feb 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding368,683,300
10 Day Avg. Volume211,251
30 Day Avg. Volume152,467
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-33.37
Price to Sales (P/S)151.05
P/FCF Ratio-4.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Cancer Diagnostics StrategyA focused blood-based cancer-detection strategy gives BCAL a defined clinical and commercial purpose. Concentration on early detection, particularly breast cancer, supports coherent product development and a route from research to market if validation succeeds.
Integrated Development PathwayBCAL covers multiple stages from research through clinical validation and commercial deployment. This integrated pathway can help align product development with evidence requirements and market access, supporting a more complete platform for future diagnostic commercialisation.
Earlier Revenue TractionThe earlier period of strong revenue growth in 2022–2023 followed by modest growth in 2024 shows that the company has previously generated commercial traction. Re-establishing that trajectory would provide an important foundation for future operating leverage.
Bears Say
Severe Revenue VolatilityThe sharp revenue collapse after earlier growth indicates that commercial traction has not been sustained. Persistently low revenue reduces operating scale, weakens the foundation for fixed-cost absorption, and makes near-term progress highly dependent on restoring demand or commercial activity.
Persistent UnprofitabilitySustained losses across EBIT, EBITDA, and net income show that the current business model is not yet economically self-supporting. Negative gross profit in 2026 is especially concerning because it suggests pressure exists before operating expenses, limiting confidence in margin recovery.
Fragile Funding PositionHeavy recurring cash burn alongside rising debt and negative equity materially reduces financial flexibility. The company may need continued external funding to sustain operations, while a weaker capital structure increases exposure to dilution and limits its ability to invest from internally generated cash.
BCAL Diagnostics Limited News
BDX FAQ
What was BCAL Diagnostics Limited’s price range in the past 12 months?
BCAL Diagnostics Limited lowest share price was AU$0.05 and its highest was AU$0.15 in the past 12 months.
What is BCAL Diagnostics Limited’s market cap?
BCAL Diagnostics Limited’s market cap is AU$33.55M.
When is BCAL Diagnostics Limited’s upcoming earnings report date?
BCAL Diagnostics Limited’s upcoming earnings report date is Feb 23, 2027 which is in 133 days.
How were BCAL Diagnostics Limited’s earnings last quarter?
BCAL Diagnostics Limited released its earnings results on Aug 28, 2026. The company reported -AU$0.009 earnings per share for the quarter.
Is BCAL Diagnostics Limited overvalued?
According to Wall Street analysts BCAL Diagnostics Limited’s price is currently Overvalued.
Does BCAL Diagnostics Limited pay dividends?
BCAL Diagnostics Limited does not currently pay dividends.
What is BCAL Diagnostics Limited’s EPS estimate?
BCAL Diagnostics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BCAL Diagnostics Limited have?
BCAL Diagnostics Limited has 368,683,300 shares outstanding.
What happened to BCAL Diagnostics Limited’s price movement after its last earnings report?
BCAL Diagnostics Limited reported an EPS of -AU$0.009 in its last earnings report. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of BCAL Diagnostics Limited?
Currently, no hedge funds are holding shares in AU:BDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BCAL Diagnostics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.33%
12-Months-Change
Fundamentals
Return on Equity
-881.94%
Trailing 12-Months
Asset Growth
-22.68%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
BCAL Diagnostics Limited
BCAL Diagnostics Limited is a biotechnology firm focused on creating an advanced, non-surgical laboratory blood test for the identification of breast cancer. Its flagship product, the BCAL test, is a lipid biomarker-based blood assay designed for potential use in breast cancer prevention strategies, early screening, and ongoing patient monitoring. This in vitro diagnostic (IVD) technology functions by detecting a unique pattern of lipid biomarkers, which are isolated from extracellular vesicles present in a patient's plasma or blood, thereby enabling the diagnosis of breast cancer cells. Established in 2010, the company's main operations are based in Sydney, Australia.
Technical Analysis
Healius Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Sonic Healthcare Limited
―
Australian Clinical Labs Ltd
―